Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Hong Kong Studies Show Tyzeka Superior To Epivir, Hepsera In Fighting HBV (China)

This article was originally published in PharmAsia News

Executive Summary

A pair of university studies in Hong Kong conclude Idenix's Tyzeka (telbivudine) for treating chronic hepatitis B is better than commonly prescribed treatments for suppressing the hepatitis B virus. The studies compared GlaxoSmithKline's Epivir (lamivudine) and Gilead's Hepsera (adefovir dipivoxil) with Tyzeka and said 60 percent of patients on the Idenix drug ended up with non-detectable HBV in their blood. The studies in the New England Journal of Medicine and the Annals of Internal Medicine found 40 percent of patients on the other two drugs achieved that outcome after a year. Tyzeka is priced between the prices of the other two. (Click here for more

Table

View full table

Tags:
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC066804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By